Pharmasurgics Overview

  • Founded
  • 2005
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A

Pharmasurgics General Information


Developer of an anti-scarring and healing treatment after surgery. The company develops and commercializes a novel treatment for preventing harmful scarring and promoting wound healing after surgery. It's product concept is based on proprietary synthetic peptides of human lactoferrin which have strong anti-inflammatory and anti-infectious properties.

Contact Information

Ownership Status
Financing Status
Formerly VC-backed
Primary Industry
Medical Supplies
Other Industries
Surgical Devices
Drug Discovery
Primary Office
  • Arvid Wallgrens Backe 20
  • 413 46 Göteborg
  • Sweden
+46 031-762 00 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Pharmasurgics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 01-Nov-2010 00.000 Completed Pre-Clinical Trials
1. Early Stage VC 28-May-2008 00.000 00.000 Completed Pre-Clinical Trials
To view Pharmasurgics’s complete valuation and funding history, request access »

Pharmasurgics Executive Team (4)

Name Title Board Seat Contact Info
Mattias Münnich Chief Financial Officer, Co-Founder & Chief Operating Officer
Inger Baltzer Ph.D Co-Founder
Kjell Olmarker Ph.D Co-Founder & Board Member
You’re viewing 3 of 4 executive team members. Get the full list »

Pharmasurgics Board Members (1)

Name Representing Role Since
Kjell Olmarker Ph.D Self Co-Founder & Board Member 000 0000
To view Pharmasurgics’s complete board members history, request access »

Pharmasurgics Former Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Karolinska Development Venture Capital Minority 000 0000 000000 0
Midroc Invest Venture Capital Minority 000 0000 000000 0
Östersjöstiftelsen Government Minority 000 0000 000000 0
To view Pharmasurgics’s complete investors history, request access »